Clinical Trial Transparency AstraZeneca R&D 1 MedImmune Way Gaithersburg, MD 20878

Date: 15 October 2014

Subject: NKTR-118 (Naloxegol) D3820C00028 study status

To Whom It May Concern,

Curtohnson

This is to confirm that Study NKTR-118 (Naloxegol) D3820C00028, Assessing the Content Validity of a Stool Symptom Screener in Patients with Chronic Opioid-Induced Constipation, was an exploratory study in which patients only participated in an interview to assess their understanding of the content (questions) in a stool symptom screener. No study drug was administered, no invasive procedures were performed, and minimal categorical data (n,%) were generated. No synopsis to this exploratory study report is available.

Sincerely,

Curt Johnson

Associate Director, Clinical Development